Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is one of the most clinically significant peptide therapeutics of the 21st century β the molecule behind Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral formulation) β and has generated landmark cardiovascular outcomes data that fundamentally changed how physicians treat metabolic disease.
GLP-1 is an endogenous incretin hormone produced in the gut in response to food intake. Native GLP-1 has a half-life of only 1β2 minutes due to degradation by DPP-4 enzymes. Semaglutide is an engineered analog with a fatty acid side chain that binds to albumin, extending its half-life to approximately 7 days β enabling once-weekly subcutaneous dosing.
Mechanism of Action
Semaglutide activates GLP-1 receptors throughout the body, producing coordinated metabolic effects:
Pancreas: Stimulates glucose-dependent insulin secretion from beta cells; suppresses glucagon from alpha cells. Because stimulation is glucose-dependent, hypoglycemia risk is low in the absence of other hypoglycemic agents.
Gastric: Slows gastric emptying, prolonging satiety after meals and reducing post-prandial glucose excursions.
Brain: Acts on hypothalamic GLP-1 receptors to reduce appetite and food-seeking behavior. The SCALE trial data suggest semaglutide reduces cravings for high-calorie foods specifically.
Cardiovascular: GLP-1 receptors are present on cardiomyocytes and arterial endothelium. The SUSTAIN-6 and SELECT trials demonstrated direct cardioprotective effects independent of weight loss.
Liver: Reduces hepatic glucose output and appears to reduce hepatic fat accumulation (NAFLD/NASH signal in early trials).
Clinical Research & Evidence
Evidence Level: π’ EL1 β Multiple large RCTs, FDA approved across multiple indications
Key Trials:
| Trial | N | Duration | Key Finding |
|---|---|---|---|
| SUSTAIN-6 | 3,297 | 2 years | 26% reduction in MACE vs. placebo in T2DM |
| STEP-1 | 1,961 | 68 weeks | 14.9% mean weight loss vs. 2.4% placebo (Wegovy dose) |
| SELECT | 17,604 | 5 years | 20% reduction in CV events in overweight/obese without diabetes |
| PIONEER-6 | 3,183 | ~16 months | Non-inferiority for CV safety; oral formulation |
| FLOW | 3,533 | ~3.4 years | 24% reduction in kidney disease progression in T2DM |
The SELECT trial (2023) was particularly landmark β demonstrating cardiovascular benefit in people with obesity but without diabetes, expanding the drugβs risk-reduction narrative beyond glucose control.
FDA-Approved Indications
- Ozempic (0.5β2 mg/week SQ): Type 2 diabetes β glycemic control; reduce CV risk in T2DM with established CVD
- Wegovy (2.4 mg/week SQ): Chronic weight management in adults with BMI β₯30, or β₯27 with weight-related comorbidity
- Rybelsus (3β14 mg/day oral): Type 2 diabetes β glycemic control
Dosing Protocols (FDA-Approved)
Subcutaneous (Ozempic / Wegovy):
- Start: 0.25 mg/week Γ 4 weeks (tolerability phase)
- Escalate monthly: 0.5 mg β 1 mg β 1.7 mg β 2 mg (Ozempic) / 2.4 mg (Wegovy)
- Inject in abdomen, thigh, or upper arm; rotate sites
Oral (Rybelsus):
- Start: 3 mg/day Γ 30 days
- Escalate: 7 mg/day β 14 mg/day
- Take on empty stomach with β€120 mL water; wait 30 min before eating
Side Effects & Contraindications
Common (>10%):
- Nausea, vomiting, diarrhea β most common during dose escalation; typically transient
- Constipation
- Injection site reactions
Serious/Monitor:
- Pancreatitis (rare; discontinue if suspected)
- Thyroid C-cell tumors (observed in rodent studies β contraindicated in personal/family history of MTC or MEN2)
- Gastroparesis-like symptoms with high doses
- Hypoglycemia (mainly when combined with insulin/sulfonylureas)
Contraindications:
- Personal/family history of medullary thyroid carcinoma (MTC) or MEN2
- Prior serious hypersensitivity to semaglutide
- Pregnancy (emerging data suggests fetal risk)
Legal & Regulatory Status
| Region | Status |
|---|---|
| United States | FDA approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021) |
| European Union | EMA approved (Ozempic 2018, Rybelsus 2020, Wegovy 2021) |
| UK | MHRA approved |
| Canada | Health Canada approved |
| Australia | TGA approved |
Compounding Note: Due to supply shortages, compounding pharmacies produced semaglutide from 2022β2024. The FDA declared the shortage resolved in 2024, after which compounded semaglutide is no longer permitted under 503A/503B except for specific documented shortage conditions.
Research Citations
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 (SELECT).
- Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019.
- Perkovic V, et al. Semaglutide and Kidney Outcomes in T2DM. N Engl J Med. 2024 (FLOW).